Assessing the effect of Adjunctive probiotics therapy for the treatment of primary hypertension in children and adolescents: A randomized, double- blind, placebo- controlled trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200608047689N3

Enrollment

Registered

2024-07-14

Start date

2024-07-15

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Essential (primary) hypertension. Essential (primary) hypertension

Interventions

Intervention 1: Intervention group: The contents of a 500 mg probiotic capsule (Milad Pharmed Gostar company under the brand name Prokid) containing 11 strains are dissolved in 10 ml of 5% dextrose wa

Eligibility

Sex/Gender

All

Age

7 Years to 18 Years

Inclusion criteria

Inclusion criteria: Essential high blood pressure I and II Age range between 7-18 years

Exclusion criteria

Exclusion criteria: Active infection Known organ damage Use of probiotics in the 3 months prior to the study Previous history of sensitivity to probiotics

Design outcomes

Primary

Measure	Time frame
Reduction of systolic blood pressure from the baseline value by 3 mm Hg. Timepoint: After 16 weeks of treatment. Method of measurement: Blood pressure measurement.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactElham Bidabadi

Rasht University of Medical Sciences

bidabadi@mail.com+98 13 3372 9104

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026